SAN CARLOS, Calif.--(BUSINESS WIRE)--Cellerant Therapeutics, Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the publication of a radiation countermeasure study demonstrating that cryopreserved, allogeneic mouse myeloid progenitor cells significantly improved survival in mice irradiated with lethal doses of radiation. The study, published on May 4, 2012 in the scientific journal, Radiation Research, represents the first report of an effective radiation countermeasure for Acute Radiation Syndrome (ARS) across a broad range of lethal radiation doses when administered as late as seven (7) days after irradiation. These results show that myeloid progenitor cells are one of the most promising radiation countermeasures among all therapeutics currently under development with respect to efficacy, timing and practicality of administration.
